Keyphrases
Core Outcome Set
99%
Chronic Kidney Disease
99%
Randomized Controlled Trial
66%
Clinical Trials
60%
Drug Development
38%
Sectional Analysis
38%
Pertuzumab
33%
Reporting Guidelines
33%
Cuban
33%
Urology
33%
Cost-plus
33%
Risk Outcomes
33%
Patient Outcomes
33%
Risk-benefit
33%
Patient Benefit
33%
Web-based Survey
33%
Drug Companies
33%
Clinical Perspective
33%
Medicare
33%
Medicaid
33%
Patient Risk
33%
Mixed Methods Evaluation
33%
Clinical Trial Registry
28%
Breast Cancer
19%
Potential Savings
16%
Instructions to Authors
14%
International Consortium
11%
Health Measurement
11%
Health-related Quality of Life
11%
Health Outcomes
11%
Health Care Costs
11%
Objective Response Rate
11%
Health Research
9%
Descriptive Statistics
8%
Adverse Events
8%
Overall Survival
8%
Off-label Use
8%
Modality-specific
7%
Treatment Quality
7%
Treatment Modalities
7%
Progressive Conditions
7%
Patient-reported Health
7%
Disease Burden
7%
Literature Search
7%
Data Extraction
7%
Trialists
7%
Disease Research
7%
Shipping Cost
5%
Online Pharmacies
5%
Pricing Model
5%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Chronic Kidney Failure
99%
Cross Sectional Study
99%
Drug Development
66%
Randomized Controlled Trial
66%
Pertuzumab
33%
Fluticasone Propionate
33%
Drug Analysis
33%
Atopic Dermatitis
33%
Prescription Drug
33%
Breast Cancer
19%
Overall Survival
11%
Adverse Event
8%
Off-Label Use
8%
Clinical Research
5%
Diseases
5%
Medicine and Dentistry
Chronic Kidney Disease
99%
Clinical Trial
95%
Cross Sectional Study
75%
Randomized Controlled Trial
66%
Urology
33%
Pertuzumab
33%
Health Care Cost
33%
Medicare
33%
Emergency Medicine
33%
Prevalence
24%
Breast Cancer
19%
Health Outcomes
15%
Quality of Life
15%
Overall Survival
11%
Adverse Event
8%
Off-Label Use
8%
Skin Disease
8%
Logistic Regression Analysis
6%
Emergency Care
6%
Reproducibility
6%
Patient Care
6%
Clinical Study
6%
Diseases
5%
